<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3F29623E-E985-4E31-B594-DEBC2CFF4E8B"><gtr:id>3F29623E-E985-4E31-B594-DEBC2CFF4E8B</gtr:id><gtr:firstName>Tracy</gtr:firstName><gtr:surname>Robson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CACE3C60-286D-41DE-B6C8-11ECB4934262"><gtr:id>CACE3C60-286D-41DE-B6C8-11ECB4934262</gtr:id><gtr:firstName>Adrien</gtr:firstName><gtr:surname>Kissenpfennig</gtr:surname><gtr:orcidId>0000-0002-9633-3111</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1D0110B4-1EFE-4F47-8047-172C83984EB8"><gtr:id>1D0110B4-1EFE-4F47-8047-172C83984EB8</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>McCarthy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FDF61362-1449-44B9-9166-8CC94A9EA196"><gtr:id>FDF61362-1449-44B9-9166-8CC94A9EA196</gtr:id><gtr:firstName>Roy</gtr:firstName><gtr:surname>Bicknell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/87AC5B12-DCF8-411B-8F88-D00BE8D037B1"><gtr:id>87AC5B12-DCF8-411B-8F88-D00BE8D037B1</gtr:id><gtr:firstName>Anita</gtr:firstName><gtr:surname>Yakkundi</gtr:surname><gtr:orcidId>0000-0001-6633-6699</gtr:orcidId><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FI006958%2F1"><gtr:id>B21FDD59-7535-4AA1-BE0E-F6415D326594</gtr:id><gtr:title>Elucidating the extracellular role of FKBPL as a regulator of angiogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/I006958/1</gtr:grantReference><gtr:abstractText>Angiogenesis, the growth of new capillary blood vessels, is an important physiological process essential for healing and reproduction. The body controls angiogenesis by maintaining a precise balance of growth and inhibitory factors in healthy tissues. When this balance is disturbed, a wide range of diseases can arise including cancer, psoriasis, age-related blindness, diabetic ulcers, cardiovascular disease, stroke, and many others. The list of diseases that have angiogenesis as an underlying mechanism grows longer every year. It is therefore important that the factors that control the angiogenic process are well understood. When angiogenic growth factors are produced in excess of angiogenesis inhibitors, the balance is tipped in favour of blood vessel growth. When inhibitors are present in excess of stimulators, angiogenesis is stopped. The normal, healthy body maintains a perfect balance of angiogenesis modulators. We have identified a novel protein, called FKBPL, that occurs naturally in the body, and has potent anti-angiogenic activity. We know this because when we add FKBPL to growing tumours it prevents their growth by stopping angiogenesis within the tumour, starving it of oxygen and nutrients. We now need to understand the precise actions of this protein in the body during blood vessel development, allowing us to understand its role in the diseases outlined above. We will therefore study the normal role of FKBPL during blood vessel development in two angiogenesis models. We will do this using a molecular technique to prevent expression of this protein and then assess the effects on blood vessel development. This will tell us how critical FKBPL is in controlling this process. We also aim to study how FKBPL is switched on and off to control blood vessel development. This is also important since if the protein is not properly regulated it will cause an imbalance in angiogenesis which may lead to disease. We also aim to understand what happens within the endothelial cells, the cells that form the inner lining of all blood vessels. We know that too much of the protein stops the cells from moving so that they cannot form new blood vessels, but we need to know how the cells signal to regulate this process. Increasing and decreasing the levels of FKBPL in endothelial cells and looking at the signalling events that take place will be important. In summary, we believe that a more detailed investigation of the role of the FKBPL protein in the normal processes involved in angiogenesis will help our understanding of a wide range of diseases that are associated with disrupted or imbalanced angiogenesis. This could have a profound effect on how we develop new treatments for a wide range of common diseases.</gtr:abstractText><gtr:technicalSummary>Angiogenesis is a tightly regulated process with key physiological roles in the body. Errors in its regulation are implicated in a wide range of pathologies. A detailed understanding of the underlying mechanisms will have a significant impact on human health, mainly in the aging population. We have identified a novel, naturally secreted protein, FKBPL, that has potent anti-angiogenic activity and demonstrated that it prevents endothelial cell migration, leading to potent inhibition of angiogenesis in growing tumours. Its activity appears to be dependent on CD44, which is distinct from the well-characterised VEGF/VEGFR-associated pathways, making it attractive in terms of drug development. However, we know very little about the normal role of FKBPL during developmental angiogenesis or under what stimulus this protein is activated/secreted to inhibit this process. The aim of this project is therefore to fully characterise the physiology of FKBPL during developmental/physiological angiogenesis using loss of function approaches and to elucidate the signalling mechanisms leading to FKBPL activation/secretion. We will characterise angiogenesis in FKBPL knockout mice or following delivery of an FKBPL inhibitory antibody or potent anti-angiogenic FKBPL-derived peptide for comparison. We will also use the well-established zebrafish model, of developmental angiogenesis. Phenotypic changes will be examined following FKBPL knock-down with targeted morpholinos or following treatment with the FKBPL peptide; the dependency on FKBPL's target, CD44 will also be assessed. Finally, at a more basic cellular level we will identify the molecular signals leading to FKBPL's secretion/extracellular activation and downstream signalling. In summary, this study will identify the role played by FKBPL during the angiogenesis, ultimately facilitating our understanding of this process in human disease.</gtr:technicalSummary><gtr:potentialImpactText>Angiogenesis is one of the main research focuses among the pharmaceutical giants. This is because angiogenesis is a key process that occurs during both physiological and pathological disease processes. It is associated with more than 70 major health conditions affecting children and in particular aging adults, in developed and developing nations. We have identified a new, anti-angiogenic protein, FKBPL, and now aim to investigate its endogenous role. The wide ranging impact this protein may have on the patients suffering from conditions associated with angiogenesis will be realised only once its physiological activities are fully characterised. In this respect, we have already generated a therapeutic peptide that is undergoing clinical development in the oncology field in collaboration with Almac Discovery. If we can demonstrate that FKBPL has a wider role within the developing vasculature, as proposed within the present study, we could expand the potential applications of our therapeutic peptide or indeed develop knock-down approaches to enhance angiogenesis in diseases where this would be appropriate such as cardiovascular disease and stroke. We will therefore ensure that new intellectual property developed within the current project is properly protected so that continued interest from pharma is maintained. We have extensive experience in this respect, having already demonstrated that we can translate basic research into meaningful clinical applications. We would then aim to publish in high impact journals with a wide readership and will ensure that any exciting data are publicised by the media. We will also ensure that the models we generate within this study are made freely available to other scientists to expand further their knowledge of the angiogenesis field. Economically our research could have huge impact, with our drug being developed by British pharma to target diseases affecting the worldwide population. Here we could have a major impact on health and well-being in the UK and worldwide.</gtr:potentialImpactText><gtr:fund><gtr:end>2014-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-04-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>456719</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Television documentary</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E927F09B-ACA6-4D72-8E21-F3D482D22115</gtr:id><gtr:impact>'Nolan' television documentary on 'The Truth about Cancer' - BBC1 Northern Irealnd</gtr:impact><gtr:outcomeId>56d96277a4a3d3.74354026</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b051gfdx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stormont visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D81B433F-0915-425D-898D-F5942708E840</gtr:id><gtr:impact>I represented the University at a showcase event at Stormont (NI parliament) . This was a
highly successful University campaign around higher education funding and was intended to showcase the best of the University in
terms of its research, innovation and teaching to MLAs. This was a policy influencing event.

The NI government chose not to increase tuition fees (in NI) after the event.</gtr:impact><gtr:outcomeId>Lqt9E13tsXz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Soapbox Science</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1C5D79B2-E250-4D64-A078-5B6BCE8FF919</gtr:id><gtr:impact>Northern Ireland's first Soapboc Science Event. Held in Botanic gardens/Ulster Museum, Belfast. Designed to increase visibility of women in science and was a showcase for QUB research; over 2000 members of the public interacted on the day.</gtr:impact><gtr:outcomeId>56d963926200c3.42416273</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://soapboxscience.org/?page_id=1654</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>media release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>63599195-B3A6-424D-B02E-0154648245C2</gtr:id><gtr:impact>press releaese based on a drug, ALM201, developed in my lab going into a phase I cancer clinical trial in Feb 2014,

This research led to a &amp;pound;13M investment in new Cancer research drug discover initiative to QUB by Invest Northern Ireland, part funded by the European Regional Development Fund and Almac Ltd.</gtr:impact><gtr:outcomeId>ADqox3dDaxQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.almacgroup.com/2013/09/almacqueen%E2%80%99s-announce-cancer-research-initiatives-representing-13-million-investment/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Belfast)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CF0B39A3-419D-4A46-8816-5688A8165DE9</gtr:id><gtr:impact>this was a training event for pupils interested in studying medicine. Acted as a facilitator for mock, Multiple Mini Interviews and OSCEs for 60 6th form pupils.

None yet</gtr:impact><gtr:outcomeId>dgneKjWx9U9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>88000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - Confidence in Concept Scheme</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DAC510BB-E344-47F4-A88A-253767AD9280</gtr:id><gtr:outcomeId>soBxrgVrE88</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for Employment and Learning Northern Ireland (DELNI)</gtr:department><gtr:description>PhD Studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Government of Northern Ireland</gtr:fundingOrg><gtr:id>D8110A10-E6B9-4733-9570-C1FB6CD9435C</gtr:id><gtr:outcomeId>PD22RczMq3F</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>403432</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Phase I/II Clinical Trial for ALM201 for the treatment of solid tumours</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:fundingRef>1303/101195315 - RD0113746</gtr:fundingRef><gtr:id>B9552720-3DD0-4438-8B54-F768173E8696</gtr:id><gtr:outcomeId>5ec8d19e5ec8d1b2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>139000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Drug Discovery Project Award</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C17372/A18475</gtr:fundingRef><gtr:id>2713E416-5AE3-402D-81D3-91560C21610D</gtr:id><gtr:outcomeId>545a04dc53f586.90787697</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Government of Northern Ireland</gtr:fundingOrg><gtr:id>7A8A4625-43CA-45D2-83E7-3CDF904384A9</gtr:id><gtr:outcomeId>56d95e6e0f1237.78641857</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for Employment and Learning Northern Ireland (DELNI)</gtr:department><gtr:description>PhD Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Government of Northern Ireland</gtr:fundingOrg><gtr:id>382306F1-9F17-402A-B883-3E43004ABB2D</gtr:id><gtr:outcomeId>MZh1YxaY7AG</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>A peptide based therapeutic, modelled on the anti-angiogenic domain has now entered phase I/II cancer clinical trial. If drug shows good tolerability and efficacy in Phase I/II clinical trial it may help improve and prolong life in cancer pateints, by slowing tumour growth. Whilst this will be tested in the ovarian cancer setting, it is likely to be efficacious in other tumour types since it targets the vasculature essentially starving tumour of oxygen and nutrients. This drug was developed in collaboration with industry, ALMAC Discovery, enhancing economic impact too. To date, no toxicity has been observed in 18 patients recruited to the dose escalation phase of the trial.</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>A50CB0F9-22EF-42AB-B701-901E5F7FD1F1</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>m-4474902585.591099de280854</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Development of therapeutic ppetides based on FKBPL as anti-angiogenics</gtr:description><gtr:grantRef>BB/I006958/1</gtr:grantRef><gtr:id>21DC39C8-E3B9-43BB-BEF0-9777AD050844</gtr:id><gtr:impact>Therapeutic peptide ALM201 about to enter phase I clinical trial in ovarian cancer (EudraCT number: 2014-001175-31)</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>545cbadc94c9d0.22535495</gtr:outcomeId><gtr:patentId>WO/2007/141533</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>FKBP-L AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Objective: The anti-tumor effects of FKBPL and its extracellular role in angiogenesis are well characterised, however its role in physiological/developmental angiogenesis and the impact of FKBPL ablation has not been evaluated. This is important as effects of some angiogenic proteins are dosage dependent. Here we evaluated the regulation of FKBPL secretion under angiogenic stimuli as well as the effect of FKBPL ablation in angiogenesis using mice and zebrafish models.
Approach and Results: FKBPL was secreted maximally by human microvascular endothelial cells and fibroblasts and this was specifically downregulated by pro-angiogenic hypoxic signals, but not by the angiogenic cytokines, VEGF or IL8. FKBPL's critical role in angiogenesis was supported by our inability to generate a Fkbpl knockout mouse, with embryonic lethality occurring prior to E8.5. However, whilst Fkbpl heterozygotic embryos showed some vasculature irregularities, the mice developed normally. In murine angiogenesis models including the ex vivo aortic ring assay, in vivo sponge assay, and tumour growth assay, Fkbpl+/- mice exhibited increased sprouting, enhanced vessel recruitment and faster tumour growth, respectively, supporting the anti-angiogenic function of FKBPL. In zebrafish, zFkbpl expression correlated with endothelial marker zFli1; its knockdown using morpholinos disrupted the vasculature and the phenotype was rescued with hFKBPL. Interestingly, this vessel disruption was ineffective when zcd44 was knocked-down supporting the dependency of zFkbpl on zCd44 in zebrafish.
In addition, we established that FKBPL+/- mice are obese, reinforcing the role of FKBPL and angiogenesis in this condition
Conclusions: FKBPL is an important regulator of angiogenesis, having an essential role in murine and zebrafish blood vessel development. Mouse models of angiogenesis, demonstrated a pro-angiogenic phenotype in Fkbpl heterozygotes. FKBPL may be associated with a host of cnditions linked to aberrant angiogenesis - obesity and cancer were examined here.</gtr:description><gtr:exploitationPathways>We established that FKBPL has a clear role in development angiogenesis with important implications for a host of conditions associated with pathological angiogenesis. We demonstrated a key obesity phenotype in FKBPL deficient mice- linked with excessive angiogenesis, this has implications for a host of obesity-related diseases associated with this protein. We have developed a therapeutic peptide ALM201 which can reverse this obesity phenotype in our FKBPL deficient and indeed wild-type mice, suggesting that ALM201 may have other therapeutic applications in addition to being an anti-tumour drug.</gtr:exploitationPathways><gtr:id>D9DD777E-CEFE-4A14-9C12-A8E96609DEAD</gtr:id><gtr:outcomeId>545ccf83a53bc2.01787786</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.qub.ac.uk/schools/SchoolofPharmacy/Research/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CTRad -CTRad is an NCRI working group set up to focus on clinical and translational issues relating to radiotherapy, as well as developing a portfolio of practice-changing trials. CTRad has also promotes translation of new discoveries into practice.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FBE1E8FE-4A1F-4B6B-99BE-E89232F0ADEA</gtr:id><gtr:impact>Changes in radiotherapy practice</gtr:impact><gtr:outcomeId>KL2yjr7Sk7P</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://ctrad.ncri.org.uk/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ALM201 Phase I Clinical Trial</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BCA1C2C7-7A40-4DA8-B89F-AFE91D9161FA</gtr:id><gtr:impact>This is a phase I/II clinical trial. In the dose escalation cohort, theer have been no associated toxicities and signs of clinical benefit.</gtr:impact><gtr:outcomeId>dsMZhKH3TTa</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.hra.nhs.uk/news/research-summaries/phase-1-alm201-in-advanced-ovarian-cancer-and-other-solid-tumours/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>ALM201 has entered a first in man cancer clinical trial in ovarian cancer patients in July 2015. The trial is ongoing</gtr:description><gtr:id>F67E68DF-6918-4DB7-AF17-1151AC0186A6</gtr:id><gtr:impact>Too early- no adverse toxicity at MTD and signs of disease stabilisation in some patients</gtr:impact><gtr:outcomeId>Vvc5CCy2Hj7</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ALM201</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>IRAS ID: 147734</gtr:ukcrnIsctnId><gtr:url>http://www.hra.nhs.uk/news/research-summaries/phase-1-alm201-in-advanced-ovarian-cancer-and-other-solid-tumours/</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The IP has now been assigned to Almac Discovery</gtr:description><gtr:id>65CEDBC8-69D1-4632-ACBC-5C8AE39CB6D9</gtr:id><gtr:impact>We have now shown in a 3200 patient cohort that FKBPL is prognostic and predictive of response to tamoxifen in breast cancer patients. We hope that this will be further validated in larger studies.</gtr:impact><gtr:outcomeId>Xi4tcbWgEan</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title> ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/25906750</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of a heterozygous FKBPL+/- mouse generated as part of this grant which shows a pro-angiogenic phenotype, as predicted. Homozgous knock-out is embryonically lethal, demonstrating the important of this gene during development.</gtr:description><gtr:id>4AFDF89A-FA99-4082-83E4-EBB110B66566</gtr:id><gtr:impact>has identified a role for FKBPL in other pathological conditions</gtr:impact><gtr:outcomeId>hk6pq4836yp</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>FKBPL +/- mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5BB4A161-A31E-4434-A280-8CDA4BE49312</gtr:id><gtr:title>Transcending epithelial and intracellular biological barriers; a prototype DNA delivery device.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93557e9a9bccc915e7d9dc9f044309b4"><gtr:id>93557e9a9bccc915e7d9dc9f044309b4</gtr:id><gtr:otherNames>McCaffrey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56d94ce4a6e3c4.50226363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2CD5BCA-5B3A-46C3-A1A4-83192B2995A9</gtr:id><gtr:title>Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b01ec180b0c30284d14d051dd97d46e8"><gtr:id>b01ec180b0c30284d14d051dd97d46e8</gtr:id><gtr:otherNames>Donley C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_5435b065b0618c7fa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1DD684E-F3E4-42E4-A029-5303EFE7187D</gtr:id><gtr:title>RALA-mediated delivery of FKBPL nucleic acid therapeutics.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c9ac9418143702cd9583dfe27b2b0b9"><gtr:id>7c9ac9418143702cd9583dfe27b2b0b9</gtr:id><gtr:otherNames>Bennett R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>56d94d12187734.55069074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14EC8D9E-E4F1-4255-973E-5DC8D2FF3666</gtr:id><gtr:title>Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter.</gtr:title><gtr:parentPublicationTitle>Radiation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c467d5727c54b784047b9bf4356b8b7"><gtr:id>0c467d5727c54b784047b9bf4356b8b7</gtr:id><gtr:otherNames>McCluskey AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-7587</gtr:issn><gtr:outcomeId>pm_5435b065b060dbfae</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9922325E-4009-484B-BC4C-47BEC1405120</gtr:id><gtr:title>Recent Research Developments in Endocrinology, Vol. 5</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45c5c2b8d1692da6091d004029d5db53"><gtr:id>45c5c2b8d1692da6091d004029d5db53</gtr:id><gtr:otherNames>A. Yakkundi, T. Robson and H.D. McKeen</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-81-7895-567-4</gtr:isbn><gtr:outcomeId>545a0109051603.05254625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28B061DA-148D-4616-AF9E-09189CD7F431</gtr:id><gtr:title>Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd565789662d77d1b41e54beb25169e"><gtr:id>3dd565789662d77d1b41e54beb25169e</gtr:id><gtr:otherNames>McClements L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_15245_25_23741069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE38F330-7B0E-49B9-B17F-13B4277A4CE8</gtr:id><gtr:title>The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a017796c5efaa31bcd2d8d6bb498f397"><gtr:id>a017796c5efaa31bcd2d8d6bb498f397</gtr:id><gtr:otherNames>Yakkundi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15245_25_23457460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B69C3829-3BFB-4A98-B390-7B7646087435</gtr:id><gtr:title>FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a017796c5efaa31bcd2d8d6bb498f397"><gtr:id>a017796c5efaa31bcd2d8d6bb498f397</gtr:id><gtr:otherNames>Yakkundi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>5675e0c54fcdf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C028FFBF-D846-4A9D-BB91-370D5AC0C17C</gtr:id><gtr:title>The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d38936289bec2e199d5d8b3fa6cfb7b7"><gtr:id>d38936289bec2e199d5d8b3fa6cfb7b7</gtr:id><gtr:otherNames>Robson T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>pm_53cbffebffe650d6c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0C12F90-E870-462F-A8E4-4129DEA9A5DF</gtr:id><gtr:title>Emerging Roles for von Willebrand Factor in Cancer Cell Biology.</gtr:title><gtr:parentPublicationTitle>Seminars in thrombosis and hemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/383a37af61324d5ec992aab697db536c"><gtr:id>383a37af61324d5ec992aab697db536c</gtr:id><gtr:otherNames>O'Sullivan JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0094-6176</gtr:issn><gtr:outcomeId>5aa697e1c7aa63.04456155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F679B8D8-6508-426B-BFED-D23A961DB8BC</gtr:id><gtr:title>FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db154e9ec160e0105e24c6b70c7caf02"><gtr:id>db154e9ec160e0105e24c6b70c7caf02</gtr:id><gtr:otherNames>Valentine A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_15245_25_21364036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00306235-BD55-4E95-99BD-DC6694E5B7CB</gtr:id><gtr:title>Targeting cancer stem cells in the clinic: Current status and perspectives.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a144032cccc1dd3d6cd54dd3d3a0e2a5"><gtr:id>a144032cccc1dd3d6cd54dd3d3a0e2a5</gtr:id><gtr:otherNames>Annett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>5aa697e1840ed7.76867836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6A6D5EB-E971-4EC7-A5CB-D30580A90FB3</gtr:id><gtr:title>The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/244c1b7e8391220a156836a146be7dd0"><gtr:id>244c1b7e8391220a156836a146be7dd0</gtr:id><gtr:otherNames>McKeen HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15245_25_21428958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31C70345-033A-4D0F-A99D-94FEA67DDB1B</gtr:id><gtr:title>Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0458262aa6db5ee09a804fe235662e0"><gtr:id>b0458262aa6db5ee09a804fe235662e0</gtr:id><gtr:otherNames>McCrudden CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa697e278de17.92819310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D62EA20D-E93B-41E4-891A-E002A02AD9CC</gtr:id><gtr:title>BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6bb94f3fde35b2aca8d5f7b5c480f2"><gtr:id>0b6bb94f3fde35b2aca8d5f7b5c480f2</gtr:id><gtr:otherNames>Byrne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn><gtr:outcomeId>5aa697e14b8903.69616553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>219A6CE7-3B03-45ED-9CA5-9B4A9C90CC63</gtr:id><gtr:title>DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97052f42adee0d6b65a49de711deaa42"><gtr:id>97052f42adee0d6b65a49de711deaa42</gtr:id><gtr:otherNames>Cole G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0939-6411</gtr:issn><gtr:outcomeId>5aa697e10309f0.82346201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71D6984C-FE2A-414C-BEF3-A3E08BD26A42</gtr:id><gtr:title>Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19764cfdb8374428fa7eb1cc7343b89f"><gtr:id>19764cfdb8374428fa7eb1cc7343b89f</gtr:id><gtr:otherNames>McCarthy HO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>5459ff1706cd41.77487688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63F74B82-38FF-493F-B671-42773560DA0F</gtr:id><gtr:title>The contribution of N2O3 to the cytotoxicity of the nitric oxide donor DETA/NO: an emerging role for S-nitrosylation.</gtr:title><gtr:parentPublicationTitle>Bioscience reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6229b8aa44be13d947e15aefcbf40ddd"><gtr:id>6229b8aa44be13d947e15aefcbf40ddd</gtr:id><gtr:otherNames>Ali AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0144-8463</gtr:issn><gtr:outcomeId>pm_15245_25_23402389</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/I006958/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>